---
title: "Obefazimod (ABX464) in Ulcerative colitis: Limitations of current therapies"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Limitations of current therapies. Topics: Summary: limitations of current therapies, Ceiling of response to current therapies, Primary nonresponse and loss of response, Continued corticosteroid use after starting advanced therapy, and 3 further topics. 7 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/limitations-of-current-therapies"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Limitations of current therapies

<a id="heading-2.2.2.1.12"></a>

## 2.2.2.1.12 Limitations of Current Therapies

<a id="topic-2.2.2.1.12-1"></a>

### Summary: limitations of current therapies

A review states that the highest response to medical therapies “ranges from 30% to 60% in clinical trials”, and another review states that “10-20% of patients still require proctocolectomy for medically refractory disease.” The ACG 2025 guideline states that up to one-fifth of patients receiving anti-TNF agents may not respond initially and that “an additional 10%–15% may lose response every year”; the ECCO 2026 guideline reports that 40% of patients on vedolizumab maintenance lose response. Among 3,562 patients initiating advanced therapy, 47.8% remained steroid-free after 12 months, and mean UC-related costs in the 12 months after initiation were $42,579. The two oral classes carry restrictions: the tofacitinib label carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis, and both U.S. JAK inhibitor labels indicate them in ulcerative colitis after an inadequate response or intolerance to one or more TNF blockers (for upadacitinib, after at least one approved systemic therapy when TNF blockers are clinically inadvisable); the S1P receptor modulators require pre-treatment assessments, and the ACG 2025 guideline states that significant cardiovascular disease and cardiac conduction defects, among other conditions, contraindicate ozanimod. Biologics require injections or intravenous infusions, which Abivax describes as resulting in “patient inconvenience and burden”.

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/); [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/); [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463); [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617); [Long et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7216775/); [Xeljanz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203214s042lbl.pdf); [Rinvoq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218347Orig1s008,211675Orig1s034lbl.pdf); [Zeposia prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209899s011s012lbl.pdf); [Velsipity prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216956s002lbl.pdf); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-2.2.2.1.12-2"></a>

### Ceiling of response to current therapies

> “Despite advances in medical therapies, the highest response to these treatments ranges from 30% to 60% in clinical trials.”

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/)

> “Although the therapeutic options are expanding, 10-20% of patients still require proctocolectomy for medically refractory disease.”

Source: [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/)

<a id="topic-2.2.2.1.12-3"></a>

### Primary nonresponse and loss of response

> “Up to one-fifth of patients receiving anti-TNF agents may not respond initially, and an additional 10%–15% may lose response every year despite an initial benefit (227,228).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

> “For anti-TNFs, 10%–13% of patients lose response annually, and dose escalation benefits 50%–75% of these patients.”
> “In patients with UC on vedolizumab maintenance therapy, 40% lose response, and approximately half will recapture response with dose escalation.”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.12-4"></a>

### Continued corticosteroid use after starting advanced therapy

> “In total, 3562 patients were included in the analysis. Most patients (83.0%) used steroids in the 12 months before initiating advanced therapy. Overall, 47.8% remained steroid-free after 12 months (excluding tapering).”
> “Mean, unadjusted, UC-related costs in the 12 months postinitiation were $42,579 and were similar between therapies.”

Source: [Long et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7216775/)

<a id="topic-2.2.2.1.12-5"></a>

### Boxed warning on Janus kinase inhibitors

> “WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS”
> “Higher rate of all-cause mortality, including sudden cardiovascular (CV) death with XELJANZ vs. TNF blockers in rheumatoid arthritis (RA) patients.”

Source: [Xeljanz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203214s042lbl.pdf)

<a id="topic-2.2.2.1.12-6"></a>

### Cardiac contraindications to sphingosine-1-phosphate receptor modulators

> “In the last 6 months, experienced myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III or IV heart failure.”
> “Assessments are required prior to initiating VELSIPITY.”

Source: [Velsipity prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216956s002lbl.pdf)

<a id="topic-2.2.2.1.12-7"></a>

### Administration burden and waning efficacy: manufacturer statement

> “Furthermore, biological agents require injections or intravenous infusions, resulting in patient inconvenience and burden, which often negatively impacts patient compliance.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
